Phase II trials of liquid levodopa/carbidopa (LD/CD) (ND0612L) by Israeli biotech NeuroDerm have shown improvements in patients with moderate to severe Parkinson’s disease.
Success with new treatment for Parkinson’s
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.